Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881184 | 0.85 | GPR84 (0.38) | SLC22A6GPR84SMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL1879945 | 0.82 | GPR84 (0.43) | SLC22A6GPR84 | |
| SCHEMBL2510902 | 0.81 | SLC22A6 (0.46) | SLC22A6GPR84SMN1; SMN2MAPTGABRR1 | |
| SCHEMBL29347458 | 0.79 | LMNA (0.34) | LMNA | |
| SCHEMBL473862 | 0.79 | GAA (0.36) | — | |
| SCHEMBL11193872 | 0.77 | SLC22A6 (0.42) | SLC22A6SMN1; SMN2GRIK1GRIK2MAPT | |
| SCHEMBL1883682 | 0.77 | SLC22A6 (0.31) | SLC22A6GPR84CPA1 | |
| SCHEMBL473722 | 0.76 | SLC22A6 (0.37) | SLC22A6GPR84SMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL19029545 | 0.75 | ANPEP (0.33) | SLC22A6 | |
| SCHEMBL1875394 | 0.73 | SLC22A6 (0.34) | SLC22A6SMN1; SMN2GRIK1GRIK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036472-A | Photocatalysis preparation method of milbelin intermediate | 山东新时代药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118726496-A | Enzymatic preparation method of milbelin intermediate | 尚科生物医药（上海）有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-2719677-B1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2412700-B1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-9206104-B2 | Methods for producing bicyclic compounds via iminium salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9162971-B2 | Methods for producing bicyclic compounds via claisen rearrangements | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-20 | — | — | US | disclosed |
| EP-2657219-B1 | Intermediate for producing bicyclic y-amino acid derivative | DAIICHI SANKYO CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2719676-A1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA IMINIUM SALT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719677-A1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2657219-A1 | Intermediate for producing bicyclic y-amino acid derivative | Daiichi Sankyo Company, Limited (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8324425-B2 | Method for producing bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2412700-A1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | SLC22A6 1629/4885GPR84 45/4885SMN1; SMN2 4663/4885 |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | ADRA2A, GABRB2, ADRB2 | SLC22A6 2457/4885GPR84 481/4885SMN1; SMN2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.